Icosavax - About the company
Icosavax is an acquired company based in Seattle (United States), founded in 2017 by Adam Simpson. It operates as a Developer of computationally designed VLP vaccines for treating multiple infections. Icosavax has raised $152M in funding from RA Capital Management and Qiming, with last known valuation of $*****. The company has 2800 active competitors, including 921 funded and 694 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.
Company Details
Developer of computationally designed VLP vaccines for treating multiple infections. The company licensed technology offers proteins that can self-assemble into virus-like particles (VLPs), for its leading candidate IVX-121, which is a vaccine for the respiratory syncytial virus and leading to improved neutralizing responses in humans. The company is also working on RSV and SARS-CoV-2 vaccine development.
- Website
- icosavax.com
- Social
- Email ID
- *****@icosavax.com
- Registered Address
- 1616 Eastlake Avenue E. Suite 208 Seattle, WA 98102
Key Metrics
Founded Year
2017
Location
Seattle, United States
Stage
Acquired
Total Funding
$152M in 4 rounds
Latest Funding Round
Last Known Valuation
$***** as on Dec 12, 2023
Investors
Ranked
872nd among 2800 active competitors
Employee Count
78,939 as on May 31, 2026
Similar Companies
Exit Details
Acquired by AstraZeneca (Dec 12, 2023)
Legal entities associated with Icosavax
Icosavax is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
ICOSAVAX, INC. CIN: 6600913 , United States, Active | Oct 31, 2017 | - | 60 (As on Dec 31, 2022) | - |
Icosavax's acquisition details
Icosavax got acquired by AstraZeneca on Dec 12, 2023 at an acquisition amount of $*****.
Click here to take a look at Icosavax's acquisition in detail
Sign up to download Icosavax's company profile
Icosavax's funding and investors
Icosavax has raised a total funding of $152M over 4 rounds. Its latest funding round was a Series B round on Apr 07, 2021 for $*****. 11 investors participated in its latest round. Icosavax has 15 institutional investors.
Here is the list of recent funding rounds of Icosavax:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Apr 07, 2021 | 7589809 | Series B | 8310504 | 5513019 | 7501727 | 8744792 |
Oct 31, 2020 | 5483791 | Grant (prize money) | 8058004 | 5854020 | 8204782 | |
Oct 03, 2019 | 8932365 | Series A | 5700862 | 5536325 |
Access funding benchmarks and valuations. Sign up today!View details of Icosavax's funding rounds and investors
Icosavax's founders and board of directors
Founder? Claim ProfileThe founders of Icosavax is Adam Simpson. Adam Simpson is the CEO of Icosavax.
Here are the details of Icosavax's key team members:
- Adam Simpson: Founder & CEO of Icosavax.
View details of Icosavax's Founder profiles and Board Members
Icosavax's employee count trend
Icosavax has 78,939 employees as of May 26. Here is Icosavax's employee count trend over the years:
Uncover Icosavax's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Icosavax's Competitors and alternates
Top competitors of Icosavax include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Icosavax, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
3rd | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
4th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
5th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
6th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
7th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
8th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
9th |  Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 71/100 | |
10th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 71/100 | |
872nd | Icosavax 2017, Seattle (United States), Acquired | Developer of computationally designed VLP vaccines for treating multiple infections | $152M | 52/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Icosavax's competitors? Click here to see the top ones
Icosavax's Investments and acquisitions
Icosavax has made no investments or acquisitions yet.
Reports related to Icosavax
Here is the latest report on Icosavax's sector:
News related to Icosavax
Filter this list•
Astrazeneca acquires Icosavax and his combined vaccine against RSV and hMPVPMFarma•Apr 26, 2024•AstraZeneca, Icosavax
•
Astrazeneca acquires biopharmaceutical company based in the USAFusoes & Aquisicoes•Feb 22, 2024•Icosavax, AstraZeneca
•
Icosavax, Inc. (NASDAQ:ICVX) Shares Bought by Barclays PLCreporter.am•Feb 17, 2024•Icosavax, Barclays
•
Halper Sadeh LLC Investigates ICVX, PGTI, IONMPR Newswire•Feb 13, 2024•Icosavax, PGT Innovations, Assure Neuromonitoring, Halper Sadeh
•
Icosavax, Inc. (NASDAQ:ICVX) CEO Adam K. Simpson Sells 15,000 Sharesetfdailynews.com•Feb 03, 2024•Icosavax
•
Kuehn Law Encourages HA, ICVX, PXD, and HARP Investors to Contact Law FirmGlobeNewswire•Jan 19, 2024•Kuehn, Hawaiian Airlines, Icosavax, Pioneer Natural Resources Company and 1 other
•
Halper Sadeh LLC Investigates ROVR, ICVX, HA, IMGNGlobeNewswire•Jan 13, 2024•Halper Sadeh, Rover, Icosavax, Hawaiian Airlines and 1 other
•
The M&A Class Action Firm Continues Investigating the Merger – HA, KRTX, EAR, ICVXGlobeNewswire•Jan 10, 2024•Monteverde, Hawaiian Airlines, Karuna Therapeutics, Eargo and 1 other
•
Halper Sadeh LLC Investigates ICVX, CVLY, PGTI, KRTXPR Newswire•Jan 09, 2024•Halper Sadeh, Icosavax, PeoplesBank, PGT Innovations and 1 other
•
The M&A Class Action Firm Continues Investigating the Merger – ICVX, PGTI, KRTX, CSTRGlobeNewswire•Jan 05, 2024•Monteverde, Icosavax, PGT Innovations, Karuna Therapeutics and 1 other
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Icosavax
Explore our recently published companies
- Secureinsure - Unfunded company
- Seattleasphaltcontractor - Unfunded company
- Seamanandkeys - Unfunded company
- Schwartzbuilders - Unfunded company
- Schatzpro - Unfunded company
- Schiedsgerichtshof - Unfunded company
